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doi:10.1016/j.jtcvs.2007.12.018462 The Journal of Thoracic and CardObjective: The aim of this prospective randomized trial was to evaluate the impact of
complete supraannular positioning of mechanical aortic bileaflet valves.
Methods:Between April of 2004 and November of 2006, 80 patients underwent aortic
valve replacement with the complete supraannular Medtronic Advantage Supra (n5
40) (Medtronic Inc, Minneapolis, Minn) or the intra-supraannular St Jude Medical
Regent (n 5 40) prosthesis (St Jude Medical Inc, St Paul, Minn). Before randomiza-
tion and valve sizing for both valve types, the aortic tissue annulus diameter was
determined by Hegar dilator. Transthoracic echocardiography data were obtained
early postoperatively and at 6 months, including stress echocardiography.
Results: By grouping the data on the basis of a patient’s tissue annulus diameter, no
significant difference of either valve was detected with regard to mean pressure gra-
dient and effective orifice area index at rest. Effective orifice area index ranged from
0.95 6 0.32 cm2/m2 to 1.27 6 0.33 cm2/m2 in the Advantage Supra group and from
0.98 6 0.36 cm2/m2 to 1.26 6 0.37 cm2/m2 in the Regent group. During exercise,
mean pressure gradients increased from 11.9 6 4.9 mm Hg to 19.1 6 7.2 mm Hg
in the Advantage Supra group and from 9.6 6 4.0 to 16.4 mm Hg 6 7.3 mm Hg in
the Regent group. A marked left ventricular mass regression across all annulus sizes
was noted in both groups (P , .001). Sizing for both valve types showed that in
26.3%, the completely supraannular valve design allows the implantation of a 1
size larger valve in label than the corresponding intra-supraannular valve.
Conclusion: By grouping the data on the basis of a patient’s tissue annulus diameter,
no significant superiority of either prosthesis was detected with regard to left ventric-
ular mass regression, effective orifice area index, and mean pressure gradient during
rest and exercise.We conclude that there is no additional benefit of supraannular valve
positioning.
A
ortic valve replacement (AVR) is the treatment of choice for advanced calci-
fied aortic valve stenosis and has developed into a routine method with a low
complication rate.1 The surgeon aims for the best hemodynamic result that is
realized by maximizing the overall area available for blood flow.
Today, several bileaflet mechanical heart valves, which are similar in design, are
available. All of them are considered to offer good hemodynamic function and almost
unlimited durability and thus serve as the current standard for mechanical heart valve
replacement.2,3 Initially, valve prostheses were designed for intra-annular placement.
However, this may reduce the available area for transvalvular blood flow and may
leave the patient with a residual pressure gradient, especially in the small-sized annulus.iovascular Surgery c August 2008
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CDAbbreviations and Acronyms
AVR 5 aortic valve replacement
EOA 5 effective orifice area
EOAI 5 effective orifice area index
EOF 5 effective orifice fraction
LV 5 left ventricular
LVM 5 left ventricular mass
LVOT 5 left ventricular outflow tract
MPG 5 mean pressure gradient
PPM 5 patient–prosthesis mismatch
Manufacturers have therefore designed intra-supraannular
valves with a reduced sewing ring, such as the St Jude Med-
ical Regent valve (St Jude Medical Inc, St Paul, Minn) in
which only the pivot guards remain intra-annular. This has
already shown excellent hemodynamic results.4,5 To further
improve the hemodynamic performance, manufacturers con-
structed complete supraannular valves in which the complete
housing is placed above the tissue annulus, such as the Med-
tronic Advantage Supra valve (Medtronic Inc, Minneapolis,
Minn). With this complete supraannular positioning, no parts
of the valve housing protrude into the outflow area and the
valve’s orifice can theoretically be the same size as the
patient’s tissue annulus (Figure 1, A and B).
However, up to the present there have been no compara-
tive studies of both valve types to show whether the complete
supraannular design offers a further advantage. Therefore,
the aim of this prospective randomized study was to evaluate
the early hemodynamic and clinical performance of these 2
mechanical aortic valve prostheses during rest and exercise,
to analyze the impact of complete supraannular valve posi-
tioning, and to evaluate prosthesis-specific differences in
valve sizing and valve size labeling.
Materials and Methods
Patients’ Enrollment
Between April of 2004 and November of 2006, 80 patients who
were diagnosed with aortic stenosis or mixed lesion that required
AVR entered the study. Patients with pure aortic regurgitation; valve
size 27 or more; emergency surgery; endocarditis; double valve re-
placement; age less than 18 years; preexisting valve prosthesis in
mitral, pulmonic, or tricuspid position; nonstudy valve surgeon; un-
favorable geographic location; or refusal of study participation were
excluded from enrolment. During surgery, patients were random-
ized to receive either the Medtronic Advantage Supra valve or the
St Jude Medical Regent valve. The study was approved by the insti-
tutional ethics committee. Informed consent was obtained from each
participant. Early follow-up was within 10 days postoperatively by
transthoracic echocardiography at rest. Six months postoperatively,
patients were followed up including transthoracic echocardiography
at rest and at stress using bicycle exercise. Valve-related complica-
tions were documented at the time of appearance. Follow-up was
100% complete.The Journal of ThoEchocardiography
Transthoracic Doppler echocardiography was performed in accor-
dance with the data requirements of the Food and Drug Administra-
tion Replacement Heart Valve Guidance, Version 4.1.6
Echocardiographic measurements performed at rest included the
transvalvular mean and maximal flow velocity, mean and maximal
pressure gradient, and velocity time integral using continuous-wave
Doppler. Pulsed-wave Doppler was used for the samemeasurements
in the left ventricular outflow tract (LVOT). LVOT diameter was
assessed from a parasternal long-axis view using an expanded
(zoom) view. The same measurements were performed during
exercise, except for LVOT diameter, which was assumed to remain
constant.
The mean systolic pressure gradient was calculated as the differ-
ence of mean aortic and mean LVOT gradient. During rest and
exercise, the flow velocity recording was first performed in the trans-
valvular jet and then in the LVOT. To ensure detection of the highest
velocities, a minimum of 2 transducer positions was attempted in all
patients. From these measurements, we calculated the left ventricu-
lar (LV) stroke volume (LVOT velocity time integral [cm] * LVOT area
[cm2]). The effective orifice area (EOA) was calculated using the
standard continuity equation. The echocardiographically obtained
hemodynamic results were referred to aortic tissue annulus diameter
(Hegar dilator measurement) instead of labeled valve size by means
of effective orifice fraction (EOF), which reflects the ratio of EOA
and aortic tissue annulus area. This procedure makes an objective
comparison of different valve types easier because of well known
differences in valve size labeling.7
LV end-systolic and end-diastolic dimensions and thickness of
the LV posterior wall and interventricular septum were assessed
in the parasternal view by multiple M-mode measurements.8 Left
ventricular mass (LVM) was calculated using the appropriate for-
mula suggested by the American Society of Echocardiography
and indexed by body surface area.9
Stress Echocardiography Protocol
Stress echocardiography was performed by bicycle exercise testing,
as described by Pibarot and colleagues10 and Eriksson and col-
leagues.11 During bicycle exercise, patients sat on a seat reclined
in a 50-degree position. The starting workload was 25 W and was
then increased by 25 W every 2 minutes. The patients were encour-
aged to exercise until exhaustion. The test was stopped if there was
no increase or an abnormal increase in blood pressure (diastolic
blood pressure .110 mm Hg), electrocardiographic evidence of is-
chemia (horizontal or downsloping S-T depression, S-T lifting), sig-
nificant arrhythmia (new atrial fibrillation, ventricular arrhythmia),
chest pain, vertigo, tachycardia (.200 beats/min minus age), or
dyspnea. To facilitate Doppler measurements during exercise, the
chest site, where optimum Doppler waveforms were recorded,
was marked before starting exercise. In case of an unsatisfactory
Doppler signal, the whole bicycle unit (ERGOLINE ergometrics
er900EL Version 05/02, Bitz, Germany) was tilted slightly to the
left side until optimal measurements were obtained. Velocity record-
ings were performed at the end of each 2-minute workload level and
were stored to the system. Blood pressure was measured noninva-
sively every 2 minutes using a sphygmomanometer cuff fixed on
the right arm. A 12-lead electrocardiogram was continuously re-
corded.7 Maximal and mean velocities, maximal pressure gradient,racic and Cardiovascular Surgery c Volume 136, Number 2 463
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CDFigure 1. A, Implant positions of the
complete supraannular Medtronic Ad-
vantage Supra (left) (Medtronic Inc,
Minneapolis, Minn) and the intra-supra-
annular St Jude Medical Regent valve
(right) (St Jude Medical Inc, St Paul,
Minn). B, Profile and dimensions (in mil-
limeters) of a labeled valve size 23. Left
side: complete supraannular Medtronic
Advantage Supra. Right side: intra-
supraannular St. Jude Med. IOD, Internal
orifice diameter; TAD, tissue annulus
diameter; ESRD, external sewing ring
diameter or aortic annulus diameter.mean pressure gradient (MPG), and velocity time integral were
calculated by loading the stored velocity recordings.
Patient–Prosthesis Mismatch
The effective orifice area index (EOAI) is the decisive parameter to
describe the incidence of patient–prosthesis mismatch (PPM). We
used the Doppler-derived EOA 6 months postoperatively to calcu-
late the EOAI. We rated the extent of PPM as not present for
EOAI greater than 0.85 cm2/m2, moderate for EOAI between 0.65
and 0.85 cm2/m2, and severe for EOAI equal to or less than 0.65
cm2/m2, as described by Pibarot and colleagues.12 This graduation
corresponds to the general concept that moderate aortic stenosis of
a native valve is present with EOAI less than 0.90 cm2/m2.13
Valve Specifications
TheMedtronic Advantage Supra valve was first implanted in July of
2003; has regulatory approvals for Europe, Canada, Australia, and
Japan; and is a development of the existing Medtronic Advantage
valve without changing the pivot region and pivot guards. By
increasing the distance between the leaflets, the Advantage valve’s
wider central opening area increases central flow, reduces turbu-
lence, and shows good hemodynamics during rest and exercise.14–16
By raising the complete housing above the tissue annulus, the whole
valve can be placed in a completely supraannular position so that the
tissue annulus contains no valve parts (Figure 1, A and B).
The St Jude Medical Regent valve is a development of the exist-
ing St Jude Medical Standard and St Jude Medical Hemodynamic
Plus valves without changing the existing design of the pivot mech-
anism or blood-contact surface areas. The St Jude Regent bileaflet
valve is designed with a reduced sewing ring to achieve a larger464 The Journal of Thoracic and Cardiovascular Surgery c AuEOA and improved hemodynamics.4,5 The cuff of the valve is raised
above the tissue annulus while the struts remain intraannular. There-
fore, the St Jude Medical Regent prosthesis will be implanted in an
intra-supraannular way (Figure 1, A and B).
Valve Sizing
After removal of the native aortic valve and decalcification of the
annulus, every surgeon determined the aortic annulus diameter by
insertion of a neutral sizer (Hegar dilator). Afterwards, sizing for
both valve types was undertaken in each patient using the appropri-
ate valve sizer provided by each manufacturer (Medtronic Advan-
tage Supra or St Jude Medical Regent). Thereby the surgeon
committed to the specific valve size before randomization.
Randomization
Randomization was performed in the operating room using the
sealed envelope technique after patient eligibility was confirmed
and valve sizing for both valve types was completed. Patients
were randomized to receive either the Medtronic Advantage Supra
or the St Jude Medical Regent valve. This protocol was designed
to prevent surgeon-specific selection bias.
Implantation Technique
AVRwas undertaken through a complete or minimally invasive par-
tial sternotomy using standard cardiopulmonary bypass under mild
hypothermia (32C) with cold crystalloid cardioplegia and topical
surface cooling. There was no difference in the operative technique
between both valve types. The mechanical prostheses were im-
planted with pledged-supported, interrupted, non-everting mattress
sutures.gust 2008
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Data are presented as mean 6 standard deviation. Comparisons
between both groups were made by the t test for independent sam-
ples in case of normal data distribution and theMann-WhitneyU test
in case of non-normal data distribution. Comparisons within 1 group
were performed by using the Wilcoxon matched-pairs test. All sta-
tistical analyses were performed with the Statistical Package for the
Social Sciences version 14.0 (SPSS Inc, Chicago, Ill).
Results
Patients
Between April of 2004 and November of 2006, 253 patients
underwent AVR with a mechanical prosthesis at the German
Heart Center Munich, Germany. A total of 173 of those pa-
tients were not able to enter the study because of exclusion cri-
teria, that is, pure aortic regurgitation (n5 17); valve size $
27 (n5 12); emergency surgery (n5 7); endocarditis (n5 20);
double valve replacement (n5 35); age, 18 years (n5 17);
preexisting valve prosthesis in mitral, pulmonic, or tricuspid
position (n5 18); nonstudy valve surgeon (n5 25); unfavor-
able geographic location (n5 8); or refusal of study participa-
tion (n5 14). Finally, 80 patients (74.4% were male) entered
the study and were randomly assigned to receive either the
Medtronic Advantage Supra valve (n 5 40) or the St Jude
Medical Regent valve (n5 40). Follow-up is 100% complete.
Aortic valve pathology was isolated stenosis (n 5 46) or
mixed lesion (n 5 34). Mean age at implantation was 55.6
6 9.3 years, and mean ejection fraction was 56.5% 6
15.8%. Both study groups did not differ significantly with re-
gard to age, gender, distribution of preoperative New York
Heart Association class, ejection fraction, and LVM index.
Preoperative data of each group are summarized in Table 1.
Operative Data and Adverse Events
The overall 30-day mortality was 1.25%. One patient died of
mesenteric ischemia in the Medtronic Advantage Supra
group. In 1 case, a Medtronic Advantage Supra valve was re-
placed intraoperatively because of suspected obstruction of
the coronary ostia. In this case, Hegar measurement revealed
an annulus diameter of 23 mm and valve sizing revealed a la-
beled valve size 23 for both prostheses. After removal of the
Medtronic Advantage Supra valve size 23, a St Jude Medical
Regent valve size 21 was implanted without any further prob-
lems. Minimally invasive partial sternotomy was performed
in 68.9% of isolated AVR. The mean aortic crossclamp
time was 72.0 6 17.2 minutes for isolated procedures and
84.8 6 21.7 minutes for combined procedures.
On the basis of equal tissue annulus diameters, labeled
valve sizes tended to be bigger in the Medtronic Advantage
Supra group (not significant) (Table 1). Valve sizing for
both valve types before randomization showed that in
26.3% the Medtronic Advantage Supra valve can be im-
planted 1 size larger in labeled size than the St Jude Medical
Regent valve. Both study groups did not differ significantlyThe Journal of Thowith regard to mortality, valve size distribution, aortic annu-
lus diameter, and aortic crossclamp time. Operative data of
each group are summarized in Table 1.
Therewas no difference in the frequency of clinical events.
There was 1 transient ischemic attack in the Medtronic
Advantage Supra group and 1 case of antithromboembolic
hemorrhage (gastrointestinal bleeding) in the St JudeMedical
Regent group. In both groups, there were no other prosthesis-
related adverse events, such as prosthetic valve endocarditis
or reoperations in the first 6 months postoperatively.
Hemodynamic Data During Rest and Exercise
MPG, EOAI, stroke volume, and EOF of the Medtronic
Advantage Supra valve and the St JudeMedical Regent valve
at discharge, grouped by aortic tissue annulus diameter, are
depicted in Table 2.
The mean systolic pressure gradients during treadmill
exercise are depicted in Figure 2, A, grouped by aortic tissue
annulus diameter and exercise level. In addition, the corre-
sponding stroke volume of each subgroup is shown to refer
potential differences in MPG to differences in volume load
(Figure 2, B). Exercise data are complete for 31 patients in
the Advantage Supra group and 35 patients in the Regent
group. Fourteen patients did not enter the exercise protocol.
One patient had an early death; 1 patient underwent valve
explant because of coronary artery malperfusion; 3 patients
refused further study participation; 9 patients were unable
to perform treadmill exercise because of severe coxarthrosis
(n 5 2), severe obesity (n 5 3), or atrial fibrillation (n 5 3);
and 1 patient had high blood pressure.
Exercise was discontinued on shortness of breath in
47.8%, an abnormal increase in blood pressure in 21.7%,
dyspnea in 13.0%, tachycardia in 13.0%, or paradoxic
decrease in blood pressure in 4.3%. The average achieved
workload was 86.36 19.2 W for the Advantage Supra group
and 87.1 6 18.6 W for the Regent group. No complications
occurred during treadmill exercise testing.
Regurgitation
Both valve prostheses exhibited only trivial regurgitation
because of the bileaflet valve design. In addition, 1 patient
in the Advantage Supra group and 1 patient in the Regent
group showed moderate paravalvular regurgitation. Both
patients show blood hemoglobin of 14 to 14.5 g/dL at pres-
ent, without the need for blood transfusion or ferric substitu-
tion. Lactate dehydrogenase value was slightly elevated in
both patients and ranged between 250 and 400 U/L. An inter-
mittent incomplete valve closure leading to a single-beat
transvalvular regurgitation, as previously described for the
Advantage prosthesis, was not observed.17
Patient–Prosthesis Mismatch
Moderate PPM was observed in 8.1% of the patients in the
Advantage Supra group and in 10.3% of the patients in theracic and Cardiovascular Surgery c Volume 136, Number 2 465
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CDTABLE 1. Preoperative and operative data
Advantage Supra (n 5 40)
(Medtronic Inc, Minneapolis, Minn)
Regent (n 5 40) (St Jude
Medical Inc, St Paul, Minn) P Value
Mean age (y)* 55.6 6 7.4 55.5 6 10.9 .943
Gender .802
Male n 5 29 n 5 30
Female n 5 11 n 5 10
Cardiac rhythm
Sinus rhythm n 5 40 n 5 36
Atrial fibrillation n 5 0 n 5 3
Paced n 5 0 n 5 1
NYHA classification
Class I n 5 1 n 5 0
Class II n 5 29 n 5 30
Class III n 5 7 n 5 10
Class IV n 5 3 n 5 0
Mean NYHA* 2.30 6 0.65 2.25 6 0.44 .688
Aortic valve lesion
Isolated stenosis n 5 20 n 5 26
Stenosis and regurgitation n 5 20 n 5 14
Ejection fraction (%)* 60.1 6 12.6 59.9 6 12.9 .937
LVM index (g/m2)* 188.0 6 64.7 206.2 6 60.7 .208
Operative mortality n 5 1 (2.5%) n 5 0 (0%) .321
Valve size (labeled)
19 n 5 0 n 5 1
21 n 5 5 n 5 9
23 n 5 15 n 5 15
25 n 5 20 n 5 15
Average labeled valve size* 23.8 6 1.4 23.2 6 1.7 .117
LVOT size (echo, mm)* 24.0 6 1.9 23.7 6 2.0 .509
Annulus-size (Hegar, mm)* 23.9 6 1.6 23.8 6 1.9 .848
Concomitant procedures
None n 5 32 n 5 29
CABG n 5 6 n 5 6
Other n 5 2 n 5 5
Partial sternotomy n 5 22 n 5 20
Aortic crossclamp (min)*
Isolated procedures 69.7 6 16.4 74.1 6 17.8 .328
Combined procedures 89.8 6 25.6 82.9 6 19.3 .525
Intraoperative adverse events 1 Medtronic Advantage Supra explantation
because of coronary artery atresia
CABG, Coronary artery bypass grafting;NYHA,New York Heart Association; LVM, left ventricular mass; LVOT, left ventricular outflow tract. *Results as means
6 standard deviation. t test for independent samples.Regent group; severe PPM was observed in 2.7% of the
patients in the Advantage Supra group and in 2.6% of the
patients in the Regent group. The incidence of PPM grouped
by aortic tissue annulus diameter is shown in Table 3.
Left Ventricular Mass Regression
The degree of LVM regression for all patients, grouped by
aortic tissue annulus diameter, is shown in Table 3. LVM
ndex regression at 6 months across all valve sizes was
14.8% in the Advantage Supra group (P , .001) and
23.9% in the Regent group (P , .001): 14.3% for 20 to 22466 The Journal of Thoracic and Cardiovascular Surgery c Aumm (P 5 not significant), 15.1% for 23 to 24 mm (P ,
.05), and 17.6% for 25 to 26 mm (P 5 not significant) in
the Advantage Supra group and 21.1% for 20 to 22 mm (P
, .05), 18.1% for 23 to 24 mm (P , .05), and 28.0% for
25 to 26 mm (P , .05) in the Regent group.
Discussion
To maximize the EOA, manufacturers have designed intra-
supraannular valves with a reduced sewing ring, such as
the St Jude Medical Regent valve, or complete supraannular
valves, such as the Medtronic Advantage Supra valve.gust 2008
Guenzinger et al Surgery for Acquired Cardiovascular DiseaseTABLE 2. Hemodynamic data at rest grouped by aortic tissue annulus diameter
Aortic tissue annulus diameter (mm)
Parameter 20–22 23–24 25–26
MPG (mm Hg)
Advantage Supra (Medtronic Inc, Minneapolis, Minn) 18.0 6 4.9 11.7 6 4.6 13.8 6 6.5
Regent (St Jude Medical Inc, St Paul, Minn) 11.9 6 7.1 10.6 6 4.2 9.7 6 3.6
SV (mL)
Advantage Supra 87.5 6 35.4 102.2 6 26.5 112.9 6 30.7
Regent 74.4 6 16.6 95.4 6 31.0 95.2 6 24.7
EOAI (cm2/m2)
Advantage Supra 0.95 6 0.32 1.22 6 0.35 1.27 6 0.33
Regent 0.98 6 0.36 1.04 6 0.32 1.26 6 0.37
EOF (%)
Advantage Supra 0.49 6 0.17 0.52 6 0.11 0.47 6 0.10
Regent 0.52 6 0.17 0.48 6 0.13 0.50 6 0.13
MPG,Mean pressure gradient; SV, stroke volume; EOAI, effective orifice area index; EOF, effective orifice fraction. Results are presented as means6 stan-
dard deviation. *P , .05, Mann-Whitney U test.A
CDIn several studies, excellent hemodynamic and clinical
data are documented for the St Jude Medical Regent valve
and thus serve as a benchmark in cardiovascular surgery.4,5
The Medtronic Advantage Supra valve, which is a further
development of the existing Medtronic Advantage valve, is
designed to be implanted in the complete supraannular
position and thus is intended to provide superior hemody-
namic performance with more complete LVM regression
and improved clinical outcome. To date, no hemodynamic
and clinical data for the Medtronic Advantage Supra valve
are available in the literature.
The aim of this prospective randomized study was to
evaluate the impact of complete supraannular valve positi-
oning of mechanical bileaflet aortic valves. Therefore we
analyzed the prosthesis-specific differences in valve sizing
and valve size labeling, the early clinical outcome, and the
hemodynamic performance during rest and exercise of a com-
plete supraannular and an intra-supraannular bileaflet aortic
valve.
Comparison of Different Valve Types
For an objective comparison of different prosthetic valve
types, several issues should be considered: First, hemo-
dynamic data and LVM regression should be based on
a patient’s aortic tissue annulus diameter. This is particularly
important when 2 different types of valve design (eg, intra-
supraannular vs complete supraannular) are compared
because the labeled valve size does not represent the geomet-
ric size of the valve (Figure 1, B). Second, valve sizing for the
prostheses should be undertaken before randomization using
the appropriate valve sizers. As such, each surgeon was
required to commit to a specific valve size before valve sel-
ection. The random assignment method used in this study
prevented surgeon-specific selection bias and achieved anThe Journal of Thoexcellent degree of uniformity in the distribution of major
preoperative and perioperative variables. Third, the EOF,
which represents the ratio of the prosthetic EOA (echocardio-
graphically obtained) and the patient’s aortic annulus area
(obtained by intraoperative measurement using the Hegar
dilator) should be determined. It objectively reflects the
EOA that can be achieved with a specific valve type in a given
patient’s aortic annulus. This index has been formerly
described in detail by our group.7,18 The EOF is advanta-
geous in comparisons between valves of varying manufac-
turers, especially since the launch of complete supraannular
prostheses. Fourth, Doppler echocardiographic evaluation
of the prosthetic heart valve function should be performed
during exercise, because the evaluation at rest does not repre-
sent the patient’s daily activities. In this context, treadmill
exercise testing is the more physiologic approach compared
with Dobutamine stress, despite some difficulties in obtain-
ing reliable images in the tachypneic exercising patient.11,19
Furthermore, we added the stroke volume for each annulus
size and exercise level to exclude differences in pressure gra-
dients between both prostheses caused by different levels of
blood flow. The stroke volumemainly influences the pressure
gradient and therefore is the most suitable reference parame-
ter for comparisons of hemodynamic data at stress.
Operative Data and Adverse Events
The overall operative (30 days) mortality was 1.25%, with 1
early death in the Advantage Supra group. This was caused
by vasopressor-induced mesenteric ischemia. An embolic
event was excluded by necropsy, and therefore this death
was not valve related. There were no late deaths or other
prosthesis-related adverse events, such as prosthetic valve
endocarditis, thromboembolism, antithromboembolic hem-
orrhage, or reoperation in either group.racic and Cardiovascular Surgery c Volume 136, Number 2 467
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CDFigure 2. A, MPGs at stress grouped by aortic tissue annulus diameter. B, Stroke volume at stress grouped by aortic
tissue annulus diameter.In this series, 1 Medtronic Advantage Supra valve had to
be replaced by another valve because of signs of myocardial
ischemia after weaning from bypass, although the coronary
arteries were without pathologic findings preoperatively.
This intraoperative complication reflects the difficulty of468 The Journal of Thoracic and Cardiovascular Surgery c Aucomplete supraannular valve positioning, which may impair
the coronary artery perfusion caused by a higher valve posi-
tion. From our experience the patient’s given anatomy has to
be taken into account if the implantation of a complete supra-
annular valve is intended, especially in the small aortic rootgust 2008
Guenzinger et al Surgery for Acquired Cardiovascular DiseaseTABLE 3. Incidence of patient–prosthesis mismatch and postoperative left ventricular mass regression grouped by aortic
tissue annulus diameter
Patient–prosthesis mismatch
Annulus Size Valve No (EOAI> 0.85 cm/m2) Moderate (EOAI # 0.85 cm/m2) Severe (EOAI # 0.65 cm/m2)
20–22 Advantage Supra (Medtronic Inc,
Minneapolis, Minn)
60% (3/5) 20% (1/5) 20% (1/5)
Regent (St Jude Medical Inc,
St Paul, Minn)
77.8% (7/9) 22.2% (2/9) 0% (0/9)
23–24 Advantage Supra 94.7% (18/19) 5.3% (1/19) 0% (0/19)
Regent 75.0% (9/12) 16.7% (2/12) 8.3% (1/12)
25–26 Advantage Supra 92.3% (12/13) 7.7% (1/13) 0% (0/13)
Regent 100% (18/18) 0% (0/18) 0% (0/18)
Left ventricular mass index (g/cm2)
Valve Preoperative 6 mo postoperative P value
All Advantage Supra 188.0 6 64.7 160.3 6 51.7 ,.001
Regent 206.2 6 60.7 157.0 6 42.2 ,.001
20–22 Advantage Supra 179.5 6 47.2 153.8 6 47.5 .068
Regent 169.0 6 53.9 133.4 6 35.3 .015
23–24 Advantage Supra 165.5 6 47.0 140.5 6 39.8 .028
Regent 188.4 6 57.8 154.3 6 39.2 .010
25–26 Advantage Supra 231.0 6 79.1 190.4 6 57.0 .075
Regent 236.7 6 52.7 170.5 6 43.6 ,.001
EOAI, Effective orifice area index. Results are presented as means 6 standard deviation.A
CDwhere the supraannular prosthesis is in close vicinity to
the coronary ostia and can therefore be responsible for intra-
operative complications.20 Otherwise, the 2.5% incidence of
coronary orifice obstruction may easily increase to a larger
percentage of patients.
Hemodynamic Data During Rest and Exercise
In regard to the hemodynamic data at rest, there is no signif-
icant superiority of either valve in MPG, stroke volume,
EOAI, and EOF when grouping the data on the basis of the
patient’s tissue annulus diameter. This means that complete
supraannular valve positioning does not provide a better
hemodynamic performance at rest, which has already been
demonstrated in a prospective randomized trial with other
types of complete supraannular and intra-supraannular
mechanical aortic valve prostheses.21
During treadmill exercise, MPGs in the Advantage Supra
group increased from 11.96 4.9 mmHg at rest to 19.16 7.2
mm Hg at 100 W workload and from 9.66 4.0 to 16.46 7.3
mmHg at 100Wworkload in the Regent group. By grouping
the data on the basis of a patient’s tissue annulus diameter, no
significant difference of either valve was detected with regard
to MPG and stroke volume during exercise.
Regurgitation
The Medtronic Advantage Supra and the St Jude Medical
Regent valve allow backflow on either side of both pivotalThe Journal of Thopoints to reduce the likelihood of thrombus formation on
the prosthesis. Therefore, in all patients we observed a triv-
ial regurgitation; in all of these cases the regurgitation was
considered to be transvalvular because of the bileaflet valve
design. In addition, 2 patients showed moderate paravalvu-
lar regurgitation. However, from our point of view there
was no need for further intervention because of the excel-
lent clinical condition of these patients. Within the Med-
tronic Advantage multicenter prospective clinical trial, an
intermittent incomplete valve closure leading to a single-
beat transvalvular regurgitation was documented by our
group for the Advantage valve.17 The Medtronic Advantage
Supra valve is a further development of the existing Med-
tronic Advantage valve. Although the pivot region and
the pivot guards were not changed, this intermittent incom-
plete valve closure was not documented in any Advantage
Supra prosthesis.
Patient–Prosthesis Mismatch
PPMwas identified as an important and independent risk fac-
tor for short-term mortality in patients undergoing AVR.22
Controversial debate exists with regard to PPM, focusing
on the long-term results after AVR.23,24 A residual stenosis
represented by low EOAI is frequently observed, especially
in the small-sized aortic tissue annulus. These findings with
regard to moderate to severe PPM are important because of
its prevalence of 19% to 70% reported in the literature.25racic and Cardiovascular Surgery c Volume 136, Number 2 469
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postoperatively was used to calculate the EOAI, the inci-
dence of moderate and severe PPM was rare in both groups
compared with the literature. Moderate PPM occurred in
8.1% in the Advantage Supra group and in 10.3% in the
Regent group. The incidence of severe PPM was 2.7% in
the Advantage Supra group and 2.6% in the Regent group.
There was no significant difference in the occurrence of mod-
erate or severe PPM between both groups. In regard to EOAI,
there is no significant difference between both valve types.
These findings suggest that these new generations of bileaflet
mechanical valves are good options to prevent PPM or
reduce its severity in the aortic position.
Left Ventricular Mass Regression
In both groups, a marked and highly significant reduction in
LVM across all tissue annulus sizes (P , .001) was demon-
strated, as well as an equal amount of mass reduction. The
extent of LVM regression within 6 months was approxi-
mately 20% in both groups. This is in accordance with other
studies focusing on AVR with mechanical prostheses and
determination of LVM by means of transthoracic echocardi-
ography 6 months postoperatively.4,14,21 Despite this mass
regression, 75.8% of the Advantage Supra population and
76.9% of the Regent population still presented with LV hy-
pertrophy, when defining LV hypertrophy with LVM index
greater than 131 g/m2 in men and greater than 100 g/m2 in
women.26 In patients with aortic valve lesions, persisting
LV hypertrophy is likely to be an independent risk factor
for long-term survival after AVR.27 The reasons for incom-
plete LVM regression include residual aortic gradient
caused by PPM, persistent hypertension, and nonhemody-
namic factors, such as genotype.28 Furthermore, conven-
tional 1- and 2-dimensional echocardiographic methods
tend to overestimate LVM, compared with magnetic reso-
nance imaging.29
Limitations
The population sizes were small, and the follow-up was only
6 months. Thus, the power to comment on clinical events is
limited. However, the population size is not expected to
affect our general conclusions about hemodynamic perfor-
mance. Doppler echocardiography may overestimate the
gradient and underestimate the EOA in bileaflet mechanical
valves because of the phenomenon of localized high
gradient.30
Conclusions
Six months after implantation, the Medtronic Advantage
Supra and the St Jude Medical Regent valve provide low
MPGs and high EOAs during rest and exercise and therefore
provide excellent options for mechanical AVR. In particular,
neither valve demonstrated a clear advantage during rest and
exercise when grouping the data on the basis of a patient’s tis-470 The Journal of Thoracic and Cardiovascular Surgery c Augsue annulus diameter. PPM was rare, even in the small-sized
annulus, and a significant LVM regression, an important
indicator for long-term survival, was observed in all patients.
With the supraannular implantation technique, the surgeon’s
attention has to be turned toward appropriate valve sizing.
Further investigation and data collection will allow the
assessment of valve performance beyond 6 months after
implantation.We recommend the pressure gradients obtained
during stress echocardiography to be referred to the stroke
volume and the hemodynamic results obtained to be referred
to the patient’s annulus diameter. We conclude that there is
no additional benefit of the supraannular valve positioning
of the Medtronic Advantage Supra valve compared with
the intra-supraannular positioning of the St Jude Medical
Regent valve.
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